(NASDAQ)
3.72
-0.0950   (-3.41%)
 
Volume (24h) Market Cap. Day Range 52w Range
484.97K 127.19M 3.55 - 3.90 1.35 - 3.99
Jan-14-21 08:56AM Do Options Traders Know Something About Synlogic (SYBX) Stock We Don't?Zacks
05:28AM What Type Of Shareholders Make Up Synlogic, Inc.'s (NASDAQ:SYBX) Share Registry?Simply Wall St.
Jan-11-21 06:30AM Synlogic Outlines Upcoming Clinical MilestonesPR Newswire
Dec-14-20 11:41AM Synlogic Announces Progress on Lymphoma DrugTheStreet.com
09:55AM Synlogic Announces Progress on Lymphoma DrugTheStreet.com
Dec-14-20 06:00AM Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing with PD-L1 Checkpoint Inhibitor in the on-going Phase 1 Study for the Treatment of Solid Tumors and LymphomaPR Newswire
Dec-09-20 06:30AM Synlogic Appoints Michael Heffernan to its Board of DirectorsPR Newswire
Dec-07-20 12:27PM Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at the American Institute of Chemical Engineers Conference on Microbiome EngineeringPR Newswire
Dec-02-20 10:47AM Is Synlogic (SYBX) A Good Stock To Buy Now?Insider Monkey
Nov-27-20 08:47AM Synlogic (SYBX) Catches Eye: Stock Jumps 12.9%Zacks
Nov-18-20 06:30AM Synlogic to Present at Upcoming Virtual Banking ConferencePR Newswire
Nov-09-20 10:04AM Earnings Beat: Synlogic, Inc. (NASDAQ:SYBX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsSimply Wall St.
Nov-05-20 08:42AM Recap: Synlogic Q3 EarningsBenzinga
07:54AM The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes ShoppingBenzinga
Nov-05-20 06:30AM Synlogic Reports Third Quarter 2020 Financial Results and Provides Business UpdatePR Newswire
Nov-04-20 04:05AM Synlogic Initiates Phase 1 Study of SYNB8802 for the Treatment of Enteric HyperoxaluriaPR Newswire
Oct-27-20 06:30AM Synlogic Announces Third Quarter 2020 Conference Call & WebcastPR Newswire
Oct-22-20 06:30AM Synlogic Presents Preclinical Data on SYNB8802 for Enteric Hyperoxaluria at American Society of Nephrology (ASN) Kidney Week 2020PR Newswire
Sep-14-20 07:00AM Synlogic Appoints David Hava, Ph.D., as Chief Scientific OfficerPR Newswire
Sep-10-20 02:15AM We're Keeping An Eye On Synlogic's (NASDAQ:SYBX) Cash Burn RateSimply Wall St.
Sep-08-20 11:46AM Synlogic to Present at Upcoming Virtual Banking ConferencesPR Newswire
Aug-28-20 09:37AM 7 Top Stocks Under $5InvestorPlace
Aug-24-20 03:30AM 2 Healthcare Stocks Under $5 That Could Deliver Triple-Digit GainsTipRanks
Aug-06-20 07:00AM Synlogic Reports Second Quarter 2020 Financial Results and Provides Business UpdatePR Newswire
Jul-31-20 02:49AM Synlogic to Present at Upcoming Virtual Banking ConferencesPR Newswire
Jul-30-20 07:00AM Synlogic Announces Promotion of Antoine 'Tony' Awad to Chief Operating Officer and Additions to Leadership TeamPR Newswire
Jul-28-20 07:30AM Synlogic Announces Second Quarter 2020 Conference Call & WebcastPR Newswire
Jun-17-20 09:38AM Edited Transcript of SYBX.OQ earnings conference call or presentation 8-May-20 12:00pm GMTThomson Reuters StreetEvents
Jun-12-20 11:19AM Is Synlogic, Inc. (SYBX) A Good Stock To Buy?Insider Monkey
Jun-01-20 05:46AM Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat TumorsPR Newswire
May-27-20 08:00AM Synlogic Hosts First Virtual R&D EventPR Newswire
May-21-20 04:02AM Synlogic to Host Virtual R&D EventPR Newswire
06:00AM Synlogic Announces Termination of AbbVie Collaboration AgreementPR Newswire
May-08-20 07:44AM Recap: Synlogic Q1 EarningsBenzinga
06:00AM Synlogic Reports First Quarter 2020 Financial Results and Provides Business UpdatePR Newswire
May-04-20 04:02AM Synlogic Announces First Quarter 2020 Conference Call and WebcastPR Newswire
Apr-01-20 07:32AM Edited Transcript of SYBX earnings conference call or presentation 12-Mar-20 9:00pm GMTThomson Reuters StreetEvents
Mar-30-20 06:00AM Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational ActivitiesPR Newswire
Mar-15-20 11:00AM Synlogic, Inc. Analysts Are Cutting Their Estimates: Here's What You Need To KnowSimply Wall St.
Mar-12-20 04:19AM Synlogic Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business UpdatePR Newswire
03:00AM Synlogic, Inc. to Host Earnings CallACCESSWIRE
Mar-11-20 04:02AM Synlogic to Present at Chardan's Virtual Microbiome Medicines SummitPR Newswire
Mar-05-20 04:02AM Synlogic Announces Fourth Quarter and Full Year 2019 Conference Call and WebcastPR Newswire
Feb-19-20 02:04AM Some Synlogic (NASDAQ:SYBX) Shareholders Have Taken A Painful 73% Share Price DropSimply Wall St.
Feb-18-20 04:02AM Synlogic Announces Participation in Upcoming Investor ConferencesPR Newswire
Jan-24-20 08:01AM Will Synlogic Continue to Surge Higher?Zacks
Jan-14-20 08:33AM BioMarin to Begin Early-Stage Study on Gene Therapy for PKUZacks
Jan-09-20 06:00AM Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline ProgramsBusiness Wire
Jan-06-20 09:20AM Can The Uptrend Continue for Synlogic?Zacks
Dec-20-19 03:29AM Here is What Hedge Funds Think About Synlogic, Inc. (SYBX)Insider Monkey
Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also involved in developing discovery-stage product candidates for inborn errors of metabolism, including maple syrup urine disease, isovaleric acidemia, and organic acidemias. It has a collaboration agreement with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; Ginkgo Bioworks to discover new living medicines to treat neurological and liver disorders. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Cap:    |  Volume (24h):